{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:24:14Z","timestamp":1787163854020,"version":"build-2736575974"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>There is lack of evidence assessing surveillance protocols to detect metastasis in patients with uveal melanoma (UM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore hypothetical surveillance schedules anchored in the real-world data of our patient cohort with known prognostication status wherein, surveillance intervals ranging from every 1-month to every 12-months were statistically analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective, cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Single center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients clinically diagnosed with UM and managed with standard of care local therapy who underwent prognostication by commercially available Gene Expression Profile (GEP) (Castle Biosciences, Friendswood, Texas, USA). Those classified as having low risk (Class 1) were offered a standard protocol (SP; hepatic ultrasonography (US) at 6-month intervals) while those with high risk (Class 2) were recommended to undergo enhanced protocol (EP) that incorporated either higher frequency (US every 3 months) or enhanced modality (EM, hepatic computed tomography\/magnetic resonance imaging).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec006\">\n                    <jats:title>Main outcome Measures<\/jats:title>\n                    <jats:p>Optimal scan interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec007\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>349 patients with median age of 62 years and 54% were male. Most patients were Class 1 (65%) and had choroidal location (75%). Median follow-up among survivors was 30.9 months (IQR: 19\u201357.9). 67 patients developed metastasis. The 5-year overall survival (OS) was 80% and the 5-year metastasis-free survival (MFS) was 71%. For Class 1 patients, 12-month scan interval was optimal as it had the minimal Euclidean distance to the point (0, 0) with a median of 2.92 months from negative to positive scan with an average of 2.83 scans per patient. For Class 2 patients, a 9-month scan interval was optimal as it minimized the Euclidean distance to the point (0, 0) with an average of 3.09 scans per patients and a median of 2.93 months from negative to positive scans. There was an association between the longer scan interval and size of metastatic lesion (&gt;=6 months versus &lt;6 months, p\u2009=\u20090.002).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec008\">\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>Our analysis suggests that the frequency of hepatic imaging for detection of metastasis can be tailored on the risk status to 12 months and 9 months for patients with low and high-risk tumors, respectively. Our study provides a framework for future studies assessing surveillance protocol designs, efficacy, and impact on patient survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0355405","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:26:41Z","timestamp":1787160401000},"page":"e0355405","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic surveillance for uveal melanoma: Approach to optimization"],"prefix":"10.1371","volume":"21","author":[{"given":"Emily C.","family":"Zabor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6604-8734","authenticated-orcid":true,"given":"Ya\u011fmur Seda","family":"Ye\u015filta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9411-0320","authenticated-orcid":true,"given":"Arun D.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"2","key":"pone.0355405.ref001","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5301\/ejo.5000049","article-title":"Initial PET\/CT staging for choroidal melanoma: AJCC correlation and second nonocular primaries in 333 patients","volume":"22","author":"A Freton","year":"2012","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"pone.0355405.ref002","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0161-6420(00)00182-2","article-title":"Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment","volume":"107","author":"S Eskelin","year":"2000","journal-title":"Ophthalmology"},{"issue":"5","key":"pone.0355405.ref003","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0161-6420(00)00607-2","article-title":"Uveal melanoma: implications of tumor doubling time","volume":"108","author":"AD Singh","year":"2001","journal-title":"Ophthalmology"},{"issue":"5","key":"pone.0355405.ref004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250939","article-title":"Uveal melanoma: Long-term survival","volume":"16","author":"T Radivoyevitch","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"pone.0355405.ref005","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archopht.119.5.670","article-title":"Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15","volume":"119","author":"Collaborative Ocular Melanoma Study Group","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"pone.0355405.ref006","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/978-1-62703-727-3_22","article-title":"A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile","volume":"1102","author":"JW Harbour","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"28","key":"pone.0355405.ref007","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1200\/JCO.24.00447","article-title":"15-gene expression profile and PRAME as integrated prognostic test for uveal melanoma: first report of collaborative ocular oncology group study no. 2 (COOG2.1)","volume":"42","author":"JW Harbour","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0355405.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcjo.2024.07.014","article-title":"Tailoring surveillance imaging in uveal melanoma based on individual metastatic risk","volume":"60","author":"A Hagstr\u00f6m","year":"2025","journal-title":"Can J Ophthalmol"},{"issue":"12","key":"pone.0355405.ref009","first-page":"1868","article-title":"Risk-stratified systemic surveillance in uveal melanoma","volume":"103","author":"JM Davanzo","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"pone.0355405.ref010","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ophtha.2025.03.019","article-title":"Surveillance for Metastasis in Low-Risk Uveal Melanoma Patients: The Need for Optimization","volume":"132","author":"A Delaney","year":"2025","journal-title":"Ophthalmology"},{"issue":"20","key":"pone.0355405.ref011","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.3390\/cancers15205025","article-title":"Surveillance for Metastasis in High-Risk Uveal Melanoma Patients: Standard versus Enhanced Protocols","volume":"15","author":"YS Ye\u015filta\u015f","year":"2023","journal-title":"Cancers (Basel)"},{"key":"pone.0355405.ref012","doi-asserted-by":"crossref","first-page":"382","DOI":"10.14694\/EdBook_AM.2013.33.382","article-title":"Surveillance options for patients with uveal melanoma following definitive management","author":"JH Francis","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"pone.0355405.ref013","doi-asserted-by":"crossref","first-page":"342","DOI":"10.5603\/NJO.2022.0054","article-title":"Diagnostic and therapeutic management of patients with ocular melanomas \u2013 recommendations of the Polish Society of Oncology","volume":"72","author":"P Rutkowski","year":"2022","journal-title":"Nowotwory Journal of Oncology"},{"issue":"5","key":"pone.0355405.ref014","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41433-022-02198-w","article-title":"Consensus statement for metastatic surveillance of uveal melanoma in Scotland","volume":"37","author":"V Chadha","year":"2023","journal-title":"Eye (Lond)"},{"key":"pone.0355405.ref015","doi-asserted-by":"crossref","first-page":"115687","DOI":"10.1016\/j.ejca.2025.115687","article-title":"Uveal Melanoma UK national guidelines: 2023 update","volume":"228","author":"TJ Carter","year":"2025","journal-title":"Eur J Cancer"},{"issue":"1","key":"pone.0355405.ref016","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/curroncol31010002","article-title":"Management of uveal melanoma: updated cancer care Alberta clinical practice guideline","volume":"31","author":"E Weis","year":"2023","journal-title":"Curr Oncol"},{"key":"pone.0355405.ref017","unstructured":"NCCN Guidelines Detail. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1488"},{"key":"pone.0355405.ref018","unstructured":"Zaman FY, Ghaus A, Shackleton M. Systemic surveillance guidelines for uveal melanoma: a systematic review. Clinical & Experimental Ophthalmology. n\/a(n\/a)."},{"issue":"8","key":"pone.0355405.ref019","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.ophtha.2012.01.045","article-title":"Liver function testing is not helpful for early diagnosis of metastatic uveal melanoma","volume":"119","author":"F Mouriaux","year":"2012","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0355405.ref020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bjophthalmol-2012-302323","article-title":"MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients","volume":"97","author":"E Marshall","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"pone.0355405.ref021","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaophthalmol.2015.4810","article-title":"Hepatic Ultrasonography for Surveillance in Patients With Uveal Melanoma","volume":"134","author":"MM Choudhary","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"pone.0355405.ref022","article-title":"Outcome of an active surveillance programme for patients (pts) with uveal melanoma (UM) after primary curative therapy (PTx): Single institution 10-year experience","volume":"29","author":"CL Lee","year":"2018","journal-title":"Annals of Oncology"},{"issue":"6","key":"pone.0355405.ref023","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"ES Rantala","year":"2019","journal-title":"Melanoma Res"},{"issue":"5","key":"pone.0355405.ref024","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000495113","article-title":"Uveal Melanoma Metastatic to the Liver: Treatment Trends and Outcomes","volume":"5","author":"LT Xu","year":"2019","journal-title":"Ocul Oncol Pathol"},{"issue":"1","key":"pone.0355405.ref025","doi-asserted-by":"crossref","DOI":"10.2217\/mmt-2020-0001","article-title":"Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling","volume":"7","author":"AC Schefler","year":"2020","journal-title":"Melanoma Manag"},{"issue":"6","key":"pone.0355405.ref026","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00432-020-03450-0","article-title":"Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)","volume":"147","author":"T Steeb","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"pone.0355405.ref027","article-title":"A retrospective analysis of 10 years of liver surveillance undertaken in uveal melanoma patients treated at the supraregional \u201cLiverpool ocular oncology centre\u201d, UK","volume":"14","author":"AC Rola","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"pone.0355405.ref028","first-page":"912","article-title":"PET\/CT screening can be an effective tool for detecting uveal melanoma metastases: Results from a population-based study","volume":"64","author":"N Chopra","year":"2023","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"9","key":"pone.0355405.ref029","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.3390\/cancers15092610","article-title":"Sensitivity and Specificity of Different Prognostic Systems in Guiding Surveillance for Metastases in Uveal Melanoma","volume":"15","author":"H Robinson","year":"2023","journal-title":"Cancers (Basel)"},{"key":"pone.0355405.ref030","unstructured":"Wells GA, Shea B, O\u2019Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"key":"pone.0355405.ref031","article-title":"Metastatic uveal melanoma surveillance: A delphi panel consensus","volume":"18","author":"J Alban","year":"2026","journal-title":"Cancers"},{"issue":"13","key":"pone.0355405.ref032","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"P Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0355405.ref033","article-title":"Uveal melanoma.","volume-title":"AJCC cancer staging manual","author":"T Kivela","year":"2017"},{"issue":"16","key":"pone.0355405.ref034","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.22.01705","article-title":"Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)","volume":"41","author":"R Olofsson Bagge","year":"2023","journal-title":"J Clin Oncol"},{"key":"pone.0355405.ref035","doi-asserted-by":"crossref","unstructured":"Olofsson Bagge R, Nelson A, Shafazand A. Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases: Results from a randomized controlled trial (the SCANDIUM trial). In: 2023.","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9512"},{"key":"pone.0355405.ref036","doi-asserted-by":"crossref","first-page":"1232787","DOI":"10.3389\/fphar.2023.1232787","article-title":"Darovasertib, a novel treatment for metastatic uveal melanoma","volume":"14","author":"L Cao","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"pone.0355405.ref037","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab Plus Ipilimumab for Treatment-Na\u00efve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","volume":"39","author":"JM Piulats","year":"2021","journal-title":"J Clin Oncol"},{"key":"pone.0355405.ref038","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1200\/JCO.2022.40.16_suppl.9510","article-title":"FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301\/301A)","volume":"40","author":"JS Zager","year":"2022","journal-title":"JCO"},{"issue":"6","key":"pone.0355405.ref039","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.oret.2020.09.015","article-title":"Conditional Survival in Uveal Melanoma","volume":"5","author":"EC Zabor","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"pone.0355405.ref040","unstructured":"National Comprehensive Cancer Network. Uveal Melanoma (Version 1.2025)."},{"issue":"6","key":"pone.0355405.ref041","first-page":"1180","article-title":"American Joint Committee on Cancer Classification of Uveal Melanoma (Anatomic Stage) Predicts Prognosis in 7,731 Patients: The 2013 Zimmerman Lecture","volume":"122","author":"CL Shields","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0355405.ref042","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaophthalmol.2020.5720","article-title":"Estimating Cured Fractions of Uveal Melanoma","volume":"139","author":"AD Singh","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"16","key":"pone.0355405.ref043","doi-asserted-by":"crossref","first-page":"14953","DOI":"10.1007\/s00432-023-05271-3","article-title":"Detection of metastases using circulating tumour DNA in uveal melanoma","volume":"149","author":"AB Beasley","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"pone.0355405.ref044","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jamaophthalmol.2022.2623","article-title":"Predicted vs Observed Metastasis-Free Survival in Individuals With Uveal Melanoma","volume":"140","author":"AD Singh","year":"2022","journal-title":"JAMA Ophthalmol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0355405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:26:50Z","timestamp":1787160410000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0355405"}},"subtitle":[],"editor":[{"given":"Vikas","family":"Khetan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0355405","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}